KBC Group NV Acquires 1,296 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

KBC Group NV boosted its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 45.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,118 shares of the biotechnology company’s stock after buying an additional 1,296 shares during the quarter. KBC Group NV’s holdings in Corcept Therapeutics were worth $208,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. M&G PLC bought a new stake in shares of Corcept Therapeutics during the 3rd quarter valued at $11,173,000. Empowered Funds LLC bought a new stake in Corcept Therapeutics during the third quarter valued at about $1,784,000. Victory Capital Management Inc. increased its position in Corcept Therapeutics by 49.2% in the third quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after buying an additional 13,787 shares in the last quarter. State Street Corp raised its stake in shares of Corcept Therapeutics by 0.6% in the third quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock worth $162,871,000 after buying an additional 19,893 shares during the period. Finally, Burney Co. raised its stake in shares of Corcept Therapeutics by 9.1% in the fourth quarter. Burney Co. now owns 473,821 shares of the biotechnology company’s stock worth $23,876,000 after buying an additional 39,657 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Finally, Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $66.91 on Wednesday. The firm’s fifty day moving average is $56.34 and its two-hundred day moving average is $47.56. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $71.29. The company has a market cap of $7.01 billion, a P/E ratio of 53.10 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Insider Transactions at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the sale, the insider now directly owns 8,494 shares in the company, valued at $481,779.68. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,011 shares of company stock valued at $1,461,568. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.